A formulation manufacturing facility of Aurobindo Pharma subsidiary Eugia Pharma Specialities close to Hyderabad has accomplished a United States Food and Drug Administration (U.S. FDA) inspection.
The inspection of the ability (Unit I) at Koltur Village, Shameerpet, was performed from July 17-26 and closed with zero observations and a classification of No Action Indicated (NAI), Aurobindo stated on Wednesday.
The improvement comes shut on the heels of the U.S. FDA issuing a Form 483 with three observations to Aurobindo Pharma’s formulation manufacturing facility right here.
On July 21, in an intimation to the inventory change, the corporate had stated the ability (Unit III) located at Bachupally village, Medchal Malkajgiri district, was inspected from July 14-21. “The observations are procedural in nature. We will respond within the stipulated timelines and work closely with U.S. FDA to close the observations at the earliest,” it had stated.
